Drug intelligence / Profile preview

Phytonormyl

Development stage: Unknown
Lead developer: UPSA
Modality: Small Molecules
Administration: Oral

Overview

Phytonormyl is a multi-ingredient dietary supplement developed by the French pharmaceutical company UPSA for the management of sleep disorders. The product features a unique tri-layer controlled-release tablet formulation containing melatonin, lemon balm (*Melissa officinalis*), and ashwagandha (*Withania somnifera*). The first layer releases melatonin rapidly (within 5 minutes) to facilitate falling asleep by regulating the circadian rhythm. The subsequent layers provide a prolonged release of ashwagandha for up to 8 hours to support sleep maintenance and relaxation. Indicated for adults, Phytonormyl is marketed as a non-addictive over-the-counter (OTC) solution to improve sleep quality and reduce nocturnal awakenings.

Brand names: Phytonormyl

Targets

GABAA (Gamma-aminobutyric acid receptor)MTNR1A (MT1)

Beyond the preview

Go deeper on Phytonormyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phytonormyl.

Explore the full profile